April 19, 2021 11:03 AM EDT

Seagen gets August PDUFA for Padcev expansions; Adaptate pulls in new cash for gamma delta T cell antibodies

Max Gelman

Senior Editor

Seagen is riding the wave of two new priority reviews straight to the FDA.

The Bothell, WA-based biotech and their partners at Astellas

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program

Regeneron makes $80M obesity deal with Hansoh

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...